CRANBURY, N.J., Sept. 7,
2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE
American: PTN), a biopharmaceutical company developing
first-in-class medicines based on molecules that modulate the
activity of the melanocortin receptor system, today announced that
management will present at H.C. Wainwright 25th Annual
Global Investment Conference taking place September 11-13, 2023 in New York, NY.
The Company presentation will be held on Wednesday, September 13, 2023 at 10:00 a.m. ET. A live webcast of the presentation
will be available on the Investors section of Palatin's website at
http://www.palatin.com. A replay of the webcast will be available
for 30 days following the presentation.
About Palatin
Palatin is a biopharmaceutical company
developing first-in-class medicines based on molecules that
modulate the activity of the melanocortin receptor systems, with
targeted, receptor-specific product candidates for the treatment of
diseases with significant unmet medical need and commercial
potential. Palatin's strategy is to develop products and then form
marketing collaborations with industry leaders to maximize their
commercial potential. For additional information regarding Palatin,
please visit Palatin's website at www.palatin.com and
follow Palatin on Twitter at @PalatinTech.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/palatin-to-present-at-the-hc-wainwright-25th-annual-global-investment-conference-301921295.html
SOURCE Palatin Technologies, Inc.